Evidence map›Paper›PMID 42256891›Full record

ArticleBioactive materials2026

BMP-7 mRNA delivered by Fibrin-CaP scaffolds activates osteogenic programs in vivo as evidenced by transcriptomic and proteomic analyses.

Claudia Del Toro Runzer, Nadia Roumans, Freek G Bouwman, Betzabeth Pereira Herrera, Berta Cillero-Pastor, Micaela Roque, Joëlle Amédée, Elise Bovine, Florence Barrère de Groot, Christian Plank and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bioactive materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Claudia Del Toro RunzerDepartment of Cell Biology-Inspired Tissue Engineering, MERLN Institute for Technology-Inspired Regenerative Medicine, Maastricht University, Maastricht, the Netherlands.
Nadia RoumansDepartment of Cell Biology-Inspired Tissue Engineering, MERLN Institute for Technology-Inspired Regenerative Medicine, Maastricht University, Maastricht, the Netherlands.
Freek G BouwmanDepartment of Human Biology, Maastricht University, Maastricht, the Netherlands.
Betzabeth Pereira HerreraDepartment of Cell Biology-Inspired Tissue Engineering, MERLN Institute for Technology-Inspired Regenerative Medicine, Maastricht University, Maastricht, the Netherlands.
Berta Cillero-PastorDepartment of Cell Biology-Inspired Tissue Engineering, MERLN Institute for Technology-Inspired Regenerative Medicine, Maastricht University, Maastricht, the Netherlands.
Micaela RoqueTissue Bioengineering Laboratory (BioTis), Inserm U1026, University of Bordeaux, Bordeaux, France.
Joëlle AmédéeTissue Bioengineering Laboratory (BioTis), Inserm U1026, University of Bordeaux, Bordeaux, France.
Elise BovineOZ Biosciences SAS, Marseille, France.
Florence Barrère de GrootKuros Biosciences BV, Bilthoven, the Netherlands.
Christian PlankEthris GmbH, Planegg, Germany.
Andrea BanfiCell and Gene Therapy, Department of Biomedicine, Basel University Hospital and University of Basel, Basel, Switzerland.
Nunzia di MaggioCell and Gene Therapy, Department of Biomedicine, Basel University Hospital and University of Basel, Basel, Switzerland.
Martijn van GriensvenDepartment of Cell Biology-Inspired Tissue Engineering, MERLN Institute for Technology-Inspired Regenerative Medicine, Maastricht University, Maastricht, the Netherlands.
Elizabeth R BalmayorMusculoskeletal Gene Therapy Laboratory, Rehabilitation Medicine Research Center, Mayo Clinic, Rochester, MN, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Two recombinant bone morphogenetic proteins (BMP-2 and BMP-7) have received FDA approval for bone-related therapies. However, their clinical performance is limited by high costs, the need for supraphysiological doses, and adverse side effects. Here, we describe a chemically modified mRNA (cmRNA) encoding BMP-7 that promotes osteogenesis and functional ossification. The BMP-7 cmRNA is delivered using optimized lipid vectors and a composite fibrin-calcium phosphate scaffold. Among several lipids evaluated, two previously unexplored lipids efficiently condense mRNA and mediate its

Indexed as

Bone healingBone morphogenetic protein 7Chemically modified mRNAEctopic bone formationLipidsOssificationOsteogenesis

Identifiers

PMID42256891
PMCPMC13241941

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.